Frontage Holdings, the Hong Kong-listed contract research organisation controlled by Tigermed, has agreed to be taken private by a consortium including Charles River Laboratories at HK$2.370 a share in cash, the parties said on 9 November 2026. The price values Frontage's 2,038.5m shares in issue at about HK$4.83bn (US$620m).
Why SanRex Limited (consortium of Charles River Laboratories, Hongkong Tigermed and Frontage chairman Dr Song Li) is buying Frontage Holdings Corporation
Charles River said the planned acquisition of Frontage's bioanalysis and DMPK businesses, based at two sites in Exton, Pennsylvania with about 340 employees, would expand its bioanalysis capabilities. The operations accounted for about 40% of Frontage's 2025 revenue of US$256.7m. Frontage said the offer gives shareholders the chance to exit at a substantial premium in a stock that has traded with limited liquidity.
Deal terms and financing
The offeror, SanRex Limited, is owned 38.27% by Charles River, 53.40% by Hongkong Tigermed and the remainder by chairman Dr Song Li and family trusts. Hongkong Tigermed's and Dr Li's scheme shares will be cancelled in exchange for paying up their offeror shares, while other holders receive cash. Scheme shareholders are also entitled to an earnout tied to the target business's 2026 and 2027 results. After implementation a separation transaction will move the Exton bioanalysis and DMPK operations to Charles River and the other businesses to Tigermed and Dr Li. Charles River said it would fund its share from its credit facility and cash.
Regulatory approvals and timing
The proposal is pre-conditional on approval by Tigermed shareholders and expiry of any US Hart-Scott-Rodino waiting period, with a pre-condition long-stop date of 30 April 2027. The scheme then needs approval from disinterested Frontage shareholders and sanction by the Grand Court of the Cayman Islands. Charles River expects completion in the first half of 2027.
Market context
Tigermed, which is listed in Shenzhen and Hong Kong, took control of Frontage in 2014. Frontage shares resumed trading on 10 November and rose sharply after the announcement, Hong Kong media reported.
